 The FDA on Wednesday gave a thumbs-up to Ascendis Pharma ASs NASDAQ: ASND long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ages one and older with growth hormone deficiency GHD who weigh at least 25.4 pounds. 